Abstract

BackgroundCo-infections of hepatitis B and C viruses are frequent with HIV due to shared routes of transmission. In most of the tertiary care health settings, HIV reactive patients are routinely tested for HBsAg and anti-HCV antibodies to rule out these co-infections. However, using the routine serological markers one can only detect active HBV infection while the occult HBV infection may be missed. There is insufficient data from India on HIV-HBV co-infection and even scarce on occult HBV infection in this group.MethodsWe estimated the burden of HBV infection in patients who were tested positive for HIV at a tertiary care centre in north India. We also attempted to determine the prevalence and clinical characteristics of occult HBV infection among these treatment-naïve patients and compare their demographic features with other HIV patients. During a period of 6 years between January 2002 to December 2007, 837 HIV positive patients (631 males and 206 females (M: F :: 3.06:1) were tested for serological markers of HBV (HBsAg) and HCV (anti-HCV antibodies) infections in our laboratory. For comparison 1000 apparently healthy, HIV-negative organ donors were also included in the study. Data on demographics, sexual behaviour, medical history, laboratory tests including the serum ALT and CD4 count of these patients were recorded. A sub-group of 53 HBsAg negative samples from HIV positive patients were assessed for anti-HBs, anti-HBc total (IgG+IgM) and HBV-DNA using a highly sensitive qualitative PCR and analysed retrospectively.ResultsOverall, 7.28% of HIV positive patients showed presence of HBsAg as compared to 1.4% in the HIV negative control group. The prevalence of HBsAg was higher (8.55%) in males than females (3.39%). The study revealed that occult HBV infection with detectable HBV-DNA was prevalent in 24.5% of patients positive for anti-HBc antibodies; being 45.5% in HBsAg negative patients. Most importantly the occult infection was seen in 20.7% patients who were positive for anti-HBs antibodies. However, in none of the seronegative patient HBV-DNA was detected. Five of the nine HBV-DNA positive (55.6%) patients showed raised alanine aminotransferase levels and 66.7% had CD4+ T cell counts below 200 cells/cumm.ConclusionsHigh prevalence of HIV-HBV co-infection was found in our patients. A sizeable number of co-infected patients remain undiagnosed, if only conventional serological markers are used. Presence of anti-HBs antibodies was not a reliable surrogate marker to rule out occult HBV infection. The most reliable method to diagnose occult HBV co-infection in HIV seropositive patients is the detection of HBV-DNA.

Highlights

  • Co-infections of hepatitis B and C viruses are frequent with Human immunodeficiency virus (HIV) due to shared routes of transmission

  • Active antiretroviral therapy (HAART) is well known to prolong the survival of HIV-infected individuals which allows a longer time for cirrhosis to develop in Hepatitis B virus (HBV) coinfected patients

  • A retrospective analysis was performed on laboratory data from 837 HIV sero-reactive patients who were tested in our laboratory from January 2002 to December 2007

Read more

Summary

Introduction

Co-infections of hepatitis B and C viruses are frequent with HIV due to shared routes of transmission. HIV infected individuals show a quantitative depletion of CD4+ T cells and an overall immune dysregulation. Hepatitis B virus (HBV) is a frequent cocontaminant with HIV, mainly because both share common modes of transmission. Active antiretroviral therapy (HAART) is well known to prolong the survival of HIV-infected individuals which allows a longer time for cirrhosis to develop in HBV coinfected patients. Withdrawal or development of resistance to drugs that are dually active against both HIV and HBV has been associated with reactivation of HBV infection and with flares of liver enzyme elevations and hepatic decompensation in patients with advanced liver disease [5,6]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call